Multiple mechanisms induce ectopic expression of LYL1 in subsets of T-ALL cell lines - PubMed (original) (raw)
Multiple mechanisms induce ectopic expression of LYL1 in subsets of T-ALL cell lines
Stefan Nagel et al. Leuk Res. 2010 Apr.
Abstract
Basic helix-loop-helix (bHLH) transcription factors are essential for lymphocytic differentiation. Here, we have analyzed the complete bHLH family in T-cell acute lymphoblastic leukemia cell lines by expression profiling. Differential expression was detected for BHLHB2, HES1, HES4, HEY1, ID1, ID2, ID3, LYL1 and TAL1, highlighting dysregulation of family members with inhibitory activity. Subsequently we focused on the mechanisms responsible for aberrant expression of LYL1 in comparison to TAL1. Quantitative genomic PCR indicated microdeletions upstream of both, TAL1 and LYL1, targeting STIL/SIL and TRMT1, respectively. Additionally, one LYL1-expressing cell line exhibited amplification of TRMT1. While deletion of STIL correlated with expression of the STIL-TAL1 fusion transcript, no TRMT-LYL1 fusion transcripts were detected in parallel with genomic rearrangements thereof. Sequence analysis of the LYL1 promoter region revealed potential binding sites for transcription factors HOXA10, LMO2 and NKX2-5. Overexpression analysis, reporter gene assays and chromatin immuno-precipitation confirmed their activating impact on LYL1 expression. In conclusion, we identified multiple mechanisms which activate LYL1 in leukemic cells, including structural genomic alterations, namely microdeletion or amplification, together with the involvement of prominent oncogenic transcription factors.
Copyright (c) 2009 Elsevier Ltd. All rights reserved.
Similar articles
- TAL1, TAL2 and LYL1: a family of basic helix-loop-helix proteins implicated in T cell acute leukaemia.
Baer R. Baer R. Semin Cancer Biol. 1993 Dec;4(6):341-7. Semin Cancer Biol. 1993. PMID: 8142619 Review. - Requirement for Lyl1 in a model of Lmo2-driven early T-cell precursor ALL.
McCormack MP, Shields BJ, Jackson JT, Nasa C, Shi W, Slater NJ, Tremblay CS, Rabbitts TH, Curtis DJ. McCormack MP, et al. Blood. 2013 Sep 19;122(12):2093-103. doi: 10.1182/blood-2012-09-458570. Epub 2013 Aug 7. Blood. 2013. PMID: 23926305 - [Abnormal expression of transcription factors LYL1 and LMO2 and interaction between them in myeloid leukemia].
Meng YS, Wei R, Ai GW, Meng XQ, Zhang YX. Meng YS, et al. Zhonghua Yi Xue Za Zhi. 2009 Apr 7;89(13):890-3. Zhonghua Yi Xue Za Zhi. 2009. PMID: 19671288 Chinese. - Lyl1 interacts with CREB1 and alters expression of CREB1 target genes.
San-Marina S, Han Y, Suarez Saiz F, Trus MR, Minden MD. San-Marina S, et al. Biochim Biophys Acta. 2008 Mar;1783(3):503-17. doi: 10.1016/j.bbamcr.2007.11.015. Epub 2007 Dec 7. Biochim Biophys Acta. 2008. PMID: 18160048
Cited by
- Transcriptional activation of prostate specific homeobox gene NKX3-1 in subsets of T-cell lymphoblastic leukemia (T-ALL).
Nagel S, Ehrentraut S, Tomasch J, Lienenklaus S, Schneider B, Geffers R, Meyer C, Kaufmann M, Drexler HG, MacLeod RA. Nagel S, et al. PLoS One. 2012;7(7):e40747. doi: 10.1371/journal.pone.0040747. Epub 2012 Jul 27. PLoS One. 2012. PMID: 22848398 Free PMC article. - DNA Methylome and Transcriptome Study of Triterpenoid CDDO in TPA-Mediated Skin Carcinogenesis Model.
Kuo HD, Wu R, Sarwar MS, Zheng M, Wang C, Sargsyan D, Suh N, Kong AT. Kuo HD, et al. AAPS J. 2022 Nov 2;24(6):115. doi: 10.1208/s12248-022-00763-5. AAPS J. 2022. PMID: 36324037 - Genomic profile of a squamous cell carcinoma ex pleomorphic adenoma compared to a head and neck squamous cell carcinoma.
Mariano FV, Saccomani LFV, Giovanetti K, Del Negro A, Kowalski LP, Krepischi ACV, Altemani A. Mariano FV, et al. Braz J Otorhinolaryngol. 2018 May-Jun;84(3):393-397. doi: 10.1016/j.bjorl.2015.11.015. Epub 2016 Feb 24. Braz J Otorhinolaryngol. 2018. PMID: 26971044 Free PMC article. No abstract available. - Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia.
Laukkanen S, Veloso A, Yan C, Oksa L, Alpert EJ, Do D, Hyvärinen N, McCarthy K, Adhikari A, Yang Q, Iyer S, Garcia SP, Pello A, Ruokoranta T, Moisio S, Adhikari S, Yoder JA, Gallagher K, Whelton L, Allen JR, Jin AH, Loontiens S, Heinäniemi M, Kelliher M, Heckman CA, Lohi O, Langenau DM. Laukkanen S, et al. Blood. 2022 Oct 27;140(17):1891-1906. doi: 10.1182/blood.2021015106. Blood. 2022. PMID: 35544598 Free PMC article. - In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL.
Laukkanen S, Grönroos T, Pölönen P, Kuusanmäki H, Mehtonen J, Cloos J, Ossenkoppele G, Gjertsen B, Øystein B, Heckman C, Heinäniemi M, Kontro M, Lohi O. Laukkanen S, et al. Blood Cancer J. 2017 Sep 8;7(9):e604. doi: 10.1038/bcj.2017.87. Blood Cancer J. 2017. PMID: 28885610 Free PMC article. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous